Multiple mechanisms mediate resistance to sorafenib in urothelial cancer

International Journal of Molecular Sciences

Volumn 15, Issue 11, 2014, Pages 20500-20517

  Knievel, Judith ^a   Schulz, Wolfgang A ^a   Greife, Annemarie ^a   Hader, Christiane ^a   Lübke, Tobias ^b,c   Schmitz, Ingo ^b,c   Albers, Peter ^a   Niegisch, Günter ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Apoptosis; Mitogen activated protein kinase (MAPK) signaling; Tyrosine kinase inhibitor; Urothelial cancer

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL) PROPYLAMINO] 3 NITROBENZENESULFONYL] BENZAMIDE; ADENOSINE TRIPHOSPHATE; APOPTOSIS REGULATORY PROTEIN; CASPASE 3; CASPASE 7; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MYELOID LEUKEMIA FACTOR 1; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RAF PROTEIN; SORAFENIB; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; FIBROBLAST; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; HEK293 CELL LINE; HUMAN; HUMAN CELL; IC50; IMMUNOHISTOCHEMISTRY; MAP KINASE ASSAY; ONCOGENE H RAS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; RNA EXTRACTION; TRANSITIONAL CELL CARCINOMA; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; BLADDER; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; URINARY BLADDER NEOPLASMS; UROTHELIUM;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; MAP KINASE SIGNALING SYSTEM; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; URINARY BLADDER; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84910145396     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms151120500     Document Type: Article

References (58)

1. Ferlay, J.; Shin, H.R.; Bray, F.; Forman, D.; Mathers, C.; Parkin, D.M. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int. J. Cancer 2010, 127, 2893-2917.
2. Witjes, J.A.; Comperat, E.; Cowan, N.C.; de Santis, M.; Gakis, G.; Lebret, T.; Ribal, M.J.; van der Heijden, A.G.; Sherif, A. EAU guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2013 guidelines. Eur. Urol. 2013, 65, 778-792.
3. Schulz, W.A. Understanding urothelial carcinoma through cancer pathways. Int. J. Cancer 2006, 119, 1513-1518.
4. Knowles, M.A. Bladder cancer subtypes defined by genomic alterations. Scand. J. Urol. Nephrol. Suppl. 2008, 42, 116-130.
5. Chow, N.H.; Liu, H.S.; Lee, E.I.C.; Chang, C.J.; Chan, S.H.; Cheng, H.L.; Tzai, T.S.; Lin, J.S.N. Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. Anticancer Res. 1997, 17, 1293-1296.
6. Xia, G.; Kumar, S.R.; Hawes, D.; Cai, J.; Hassanieh, L.; Groshen, S.; Zhu, S.; Masood, R.; Quinn, D.I.; Broek, D., et al. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J. Urol. 2006, 175, 1245-1252.
7. Yang, C.C.; Chu, K.C.; Yeh, W.M. The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression. Urol. Oncol. 2004, 22, 1-6.
8. Jebar, A.H.; Hurst, C.D.; Tomlinson, D.C.; Johnston, C.; Taylor, C.F.; Knowles, M.A. FGFR3 and RAS gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 2005, 24, 5218-5225.
9. Otto, K.B.; Acharya, S.S.; Robinson, V.L. Stress-activated kinase pathway alteration is a frequent event in bladder cancer. Urol. Oncol. 2012, 30, 415-420.
10. Wilhelm, S.; Carter, C.; Lynch, M.; Lowinger, T.; Dumas, J.; Smith, R.A.; Schwartz, B.; Simantov, R.; Kelley, S. Discovery and development of sorafenib: A multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 2006, 5, 835-844.
11. European Medicines Agency. Available online: http://www.Ema.Europa.Eu/ema/index.Jsp?Curl= pages/medicines/human/medicines/000690/human_med_000929.Jsp&mid=wc0b01ac058001d124 (accessed on 28 october 2014).
12. National Cancer Institute. Available online: http://www.Cancer.Gov/cancertopics/druginfo/fdasorafenib-tosylate (accessed on 28 october 2014).
13. Krege, S.; Rexer, H.; vom Dorp, F.; de Geeter, P.; Klotz, T.; Retz, M.; Heidenreich, A.; Kuhn, M.; Kamradt, J.; Feyerabend, S., et al. Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: Suse (AUO-AB 31/05). BJU Int. 2014, 113, 429-436.
14. Sridhar, S.S.; Winquist, E.; Eisen, A.; Hotte, S.J.; McWhirter, E.; Tannock, I.F.; Mukherjee, S.D.; Wang, L.S.; Blattler, C.; Wright, J.J., et al. A phase II trial of sorafenib in first-line metastatic urothelial cancer: A study of the PMH phase II consortium. Investig. New Drug 2011, 29, 1045-1049.
15. Dreicer, R.; Li, H.L.; Stein, M.; di Paola, R.; Eleff, M.; Roth, B.J.; Wilding, G. Phase 2 trial of sorafenib in patients with advanced urothelial cancer a trial of the eastern cooperative oncology group. Cancer 2009, 115, 4090-4095.
16. Liu, L.; Cao, Y.; Chen, C.; Zhang, X.; McNabola, A.; Wilkie, D.; Wilhelm, S.; Lynch, M.; Carter, C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006, 66, 11851-11858.
17. Murphy, D.A.; Makonnen, S.; Lassoued, W.; Feldman, M.D.; Carter, C.; Lee, W.M. Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). Am. J. Pathol. 2006, 169, 1875-1885.
18. Kopparapu, P.K.; Boorjian, S.A.; Robinson, B.D.; Downes, M.; Gudas, L.J.; Mongan, N.P.; Persson, J.L. Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer. Anticancer Res. 2013, 33, 2381-2390.
19. Yang, S.; Wu, X.; Luo, C.; Pan, C.; Pu, J. Expression and clinical significance of hepacam and VEGF in urothelial carcinoma. World J. Urol. 2010, 28, 473-478.
20. Went, P.T.; Dirnhofer, S.; Bundi, M.; Mirlacher, M.; Schraml, P.; Mangialaio, S.; Dimitrijevic, S.; Kononen, J.; Lugli, A.; Simon, R., et al. Prevalence of KIT expression in human tumors. J. Clin. Oncol. 2004, 22, 4514-4522.
21. Lee, J.S.; Leem, S.H.; Lee, S.Y.; Kim, S.C.; Park, E.S.; Kim, S.B.; Kim, S.K.; Kim, Y.J.; Kim, W.J.; Chu, I.S. Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J. Clin. Oncol. 2010, 28, 2660-2667.
22. Uhlen, M.; Oksvold, P.; Fagerberg, L.; Lundberg, E.; Jonasson, K.; Forsberg, M.; Zwahlen, M.; Kampf, C.; Wester, K.; Hober, S., et al. Towards a knowledge-based human protein atlas. Nat. Biotechnol. 2010, 28, 1248-1250.
23. Choi, W.; Porten, S.; Kim, S.; Willis, D.; Plimack, E.R.; Hoffman-Censits, J.; Roth, B.; Cheng, T.; Tran, M.; Lee, I.L., et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 2014, 25, 152-165.
24. Rose, A.; Grandoch, M.; vom Dorp, F.; Ruben, H.; Rosenkranz, A.; Fischer, J.W.; Weber, A.A. Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells. Br. J. Pharmacol. 2010, 160, 1690-1698.
25. Cox, A.D.; Der, C.J. The RAF inhibitor paradox: Unexpected consequences of targeted drugs. Cancer Cell 2010, 17, 221-223.
26. Swiatkowski, S.; Seifert, H.H.; Steinhoff, C.; Prior, A.; Thievessen, I.; Schliess, F.; Schulz, W.A. Activities of MAP-kinase pathways in normal uroepithelial cells and urothelial carcinoma cell lines. Exp. Cell Res. 2003, 282, 48-57.
27. Varley, C.; Hill, G.; Pellegrin, S.; Shaw, N.J.; Selby, P.J.; Trejdosiewicz, L.K.; Southgate, J. Autocrine regulation of human urothelial cell proliferation and migration during regenerative responses in vitro. Exp. Cell Res. 2005, 306, 216-229.
28. Pinto-Leite, R.; Carreira, I.; Melo, J.; Ferreira, S.I.; Ribeiro, I.; Ferreira, J.; Filipe, M.; Bernardo, C.; Arantes-Rodrigues, R.; Oliveira, P., et al. Genomic characterization of three urinary bladder cancer cell lines: Understanding genomic types of urinary bladder cancer. Tumour Biol. 2014, 35, 4599-4617.
29. Sturm, O.E.; Orton, R.; Grindlay, J.; Birtwistle, M.; Vyshemirsky, V.; Gilbert, D.; Calder, M.; Pitt, A.; Kholodenko, B.; Kolch, W. The mammalian MAPK/ERK pathway exhibits properties of a negative feedback amplifier. Sci. Signal 2010, 3, ra90.
30. Nawroth, R.; Stellwagen, F.; Schulz, W.A.; Stoehr, R.; Hartmann, A.; Krause, B.J.; Gschwend, J.E.; Retz, M. S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer. PLoS One 2011, 6, e27509.
31. Ramirez-Labrada, A.; Lopez-Royuela, N.; Jarauta, V.; Galan-Malo, P.; Azaceta, G.; Palomera, L.; Pardo, J.; Anel, A.; Marzo, I.; Naval, J. Two death pathways induced by sorafenib in myeloma cells: Puma-mediated apoptosis and necroptosis. Clin. Transl. Oncol. 2014, dio:10.1007/s12094-014-1201-y. Available online: http://link.springer.com/article/10.1007/s12094-014-1201-y (accessed on 19 July 2014).
32. Llobet, D.; Eritja, N.; Yeramian, A.; Pallares, J.; Sorolla, A.; Domingo, M.; Santacana, M.; Gonzalez-Tallada, F.J.; Matias-Guiu, X.; Dolcet, X. The multikinase inhibitor sorafenib induces apoptosis and sensitises endometrial cancer cells to trail by different mechanisms. Eur. J. Cancer 2010, 46, 836-850.
33. Yu, C.; Bruzek, L.M.; Meng, X.W.; Gores, G.J.; Carter, C.A.; Kaufmann, S.H.; Adjei, A.A. The role of Mcl-11 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 2005, 24, 6861-6869.
34. Irmler, M.; Thome, M.; Hahne, M.; Schneider, P.; Hofmann, K.; Steiner, V.; Bodmer, J.L.; Schroter, M.; Burns, K.; Mattmann, C., et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997, 388, 190-195.
35. Scaffidi, C.; Schmitz, I.; Krammer, P.H.; Peter, M.E. The role of c-FLIP in modulation of CD95-induced apoptosis. J. Biol. Chem. 1999, 274, 1541-1548.
36. Fulda, S. Targeting c-FLICE-like inhibitory protein (CFLAR) in cancer. Expert Ther. Targets 2013, 17, 195-201.
37. Safa, A.R. C-FLIP, a master anti-apoptotic regulator. Exp. Oncol. 2012, 34, 176-184.
38. Chan, S.L.; Yu, V.C. Proteins of the Bcl-2 family in apoptosis signalling: From mechanistic insights to therapeutic opportunities. Clin. Exp. Pharmacol. Physiol. 2004, 31, 119-128.
39. Zhang, G.; Park, M.A.; Mitchell, C.; Hamed, H.; Rahmani, M.; Martin, A.P.; Curiel, D.T.; Yacoub, A.; Graf, M.; Lee, R., et al. Vorinostat and sorafenib synergistically kill tumor cells via flip suppression and CD95 activation. Clin. Cancer Res. 2008, 14, 5385-5399.
40. Muhlethaler-Mottet, A.; Meier, R.; Flahaut, M.; Bourloud, K.B.; Nardou, K.; Joseph, J.M.; Gross, N. Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells. Mol. Cancer 2008, 7, 55.
41. Kretzner, L.; Scuto, A.; Dino, P.M.; Kowolik, C.M.; Wu, J.; Ventura, P.; Jove, R.; Forman, S.J.; Yen, Y.; Kirschbaum, M.H. Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels. Cancer Res. 2011, 71, 3912-3920.
42. Hurwitz, J.L.; Stasik, I.; Kerr, E.M.; Holohan, C.; Redmond, K.M.; McLaughlin, K.M.; Busacca, S.; Barbone, D.; Broaddus, V.C.; Gray, S.G., et al. Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent. Eur. J. Cancer 2012, 48, 1096-1107.
43. Rosik, L.; Niegisch, G.; Fischer, U.; Jung, M.; Schulz, W.A.; Hoffmann, M.J. Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells. Cancer Biol. Ther. 2014, 15, 742-757.
44. Dumont, S.N.; Yang, D.; Dumont, A.G.; Reynoso, D.; Blay, J.Y.; Trent, J.C. Targeted polytherapy in small cell sarcoma and its association with doxorubicin. Mol. Oncol. 2014, doi:10.1016/j.molonc.2014.05.016.
45. Park, M.A.; Zhang, G.; Martin, A.P.; Hamed, H.; Mitchell, C.; Hylemon, P.B.; Graf, M.; Rahmani, M.; Ryan, K.; Liu, X., et al. Vorinostat and sorafenib increase er stress, autophagy and apoptosis via ceramide-dependent CD95 and perk activation. Cancer Biol. Ther. 2008, 7, 1648-1662.
46. Yuan, H.; Li, A.J.; Ma, S.L.; Cui, L.J.; Wu, B.; Yin, L.; Wu, M.C. Inhibition of autophagy significantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells. World J. Gastroenterol. 2014, 20, 4953-4962.
47. Kim, M.J.; Kim, D.E.; Jeong, I.G.; Choi, J.; Jang, S.; Lee, J.H.; Ro, S.; Hwang, J.J.; Kim, C.S. HDAC inhibitors synergize anti-proliferative effect of sorafenib in renal cell carcinoma cells. Anticancer Res. 2012, 32, 3161-3168.
48. Perabo, F.G.; Kamp, S.; Schmidt, D.; Lindner, H.; Steiner, G.; Mattes, R.H.; Wirger, A.; Pegelow, K.; Albers, P.; Kohn, E.C., et al. Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformation. Br. J. Cancer 2001, 84, 1330-1338.
49. Maas, S.; Warskulat, U.; Steinhoff, C.; Mueller, W.; Grimm, M.O.; Schulz, W.A.; Seifert, H.H. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status. Urology 2004, 63, 392-397.
50. Ewald, F.; Ueffing, N.; Brockmann, L.; Hader, C.; Telieps, T.; Schuster, M.; Schulz, W.A.; Schmitz, I. The role of c-FLIP splice variants in urothelial tumours. Cell Death Dis. 2011, 2, e245.
51. Hikita, H.; Takehara, T.; Shimizu, S.; Kodama, T.; Shigekawa, M.; Iwase, K.; Hosui, A.; Miyagi, T.; Tatsumi, T.; Ishida, H., et al. The Bcl-XL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib. Hepatology 2010, 52, 1310-1321.
52. Rahmani, M.; Aust, M.M.; Attkisson, E.; Williams, D.C., Jr.; Ferreira-Gonzalez, A.; Grant, S. Inhibition of Bcl-2 anti-apoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process. Blood 2012, 119, 6089-6098.
53. Oltersdorf, T.; Elmore, S.W.; Shoemaker, A.R.; Armstrong, R.C.; Augeri, D.J.; Belli, B.A.; Bruncko, M.; Deckwerth, T.L.; Dinges, J.; Hajduk, P.J., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435, 677-681.
54. Schwickart, M.; Huang, X.; Lill, J.R.; Liu, J.; Ferrando, R.; French, D.M.; Maecker, H.; O’Rourke, K.; Bazan, F.; Eastham-Anderson, J., et al. Deubiquitinase USP9X stabilizes Mcl1 and promotes tumour cell survival. Nature 2010, 463, 103-107.
55. Seifert, H.H.; Meyer, A.; Cronauer, M.V.; Hatina, J.; Muller, M.; Rieder, H.; Hoffmann, M.J.; Ackermann, R.; Schulz, W.A. A new and reliable culture system for superficial low-grade urothelial carcinoma of the bladder. World J. Urol. 2007, 25, 297-302.
56. Janssen, K.; Pohlmann, S.; Janicke, R.U.; Schulze-Osthoff, K.; Fischer, U. Apaf-1 and caspase-9 deficiency prevents apoptosis in a Bax-controlled pathway and promotes clonogenic survival during paclitaxel treatment. Blood 2007, 110, 3662-3672.
57. Weinstein, J.N.; Akbani, R.; Broom, B.M.; Wang, W.; Verhaak, R.G.W.; Liu, W.; Ju, Z.; Motter, T.; Peng, B.; Ryan, M., et al. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014, 507, 315-322.
58. Guo, G.; Sun, X.; Chen, C.; Wu, S.; Huang, P.; Li, Z.; Dean, M.; Huang, Y.; Jia, W.; Zhou, Q., et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat. Genet. 2013, 45, 1459-1463.